Viking Therapeutics outlines completion of VANQUISH-1 enrollment by year-end while advancing novel VK2735 maintenance dosing study (NASDAQ:VKTX)
Viking Therapeutics(US:VKTX) Seeking Alpha·2025-10-23 07:34To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...